Acurx Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview
09/05/2025 16:24
Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to show no change in quarterly revenue when it reports results on May 13 for the period ending March 31 2025 ​LSEG's mean analyst estimate for Acurx Pharmaceuticals Inc is for a loss of 15 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $5.00​, above​ its last closing price of $0.38. ​​​ Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.18 | -0.16 | Beat | 11.1 | |
| Sep. 30 2024 | -0.23 | -0.20 | -0.17 | Beat | 15 |
| Jun. 30 2024 | -0.22 | -0.22 | -0.26 | Missed | -18.2​ |
| Mar. 31 2024 | -0.24 | -0.24 | -0.28 | Missed | -16.7 |
| ​​Dec. 31 2023 | -0.26 | -0.37 | Missed | -42.3 | |
| Sep. 30 2023 | -0.28 | -0.27 | -0.24 | Beat | 11.1​ |
| Jun. 30 2023 | -0.27 | -0.27 | -0.28 | Missed | -3.7 |
| Mar. 31 2023 | -0.30 | -0.29 | -0.25 | Beat | 15.3 |
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln